(Q46611942)

23 December 2017

title

Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study (English)

1 reference

23 December 2017

1 reference

Yining Huang

1

1 reference

23 December 2017

Yan Cheng

2

1 reference

23 December 2017

Jiang Wu

3

1 reference

23 December 2017

Yansheng Li

4

1 reference

23 December 2017

En Xu

5

1 reference

23 December 2017

Zhen Hong

6

1 reference

23 December 2017

Zhengyi Li

7

1 reference

23 December 2017

Weiwei Zhang

8

1 reference

23 December 2017

Meiping Ding

9

1 reference

23 December 2017

Xuguang Gao

10

1 reference

23 December 2017

Dongsheng Fan

11

1 reference

23 December 2017

Jinsheng Zeng

12

1 reference

23 December 2017

Kasing Wong

13

1 reference

23 December 2017

Chuanzhen Lu

14

1 reference

23 December 2017

Jiangxi Xiao

15

1 reference

23 December 2017

Chen Yao

16

1 reference

23 December 2017

Cilostazol versus Aspirin for Secondary Ischaemic Stroke Prevention cooperation investigators

17

1 reference

23 December 2017

publication date

2 May 2008

1 reference

23 December 2017

published in

Lancet Neurology

1 reference

23 December 2017

volume

7

1 reference

23 December 2017

issue

6

1 reference

23 December 2017

page(s)

494-499

1 reference

23 December 2017

Incidence and trends of stroke and its subtypes in China: results from three large cities

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970094-2

7 January 2021

Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970094-2

7 January 2021

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970094-2

7 January 2021

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970094-2

7 January 2021

Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970094-2

7 January 2021

Proportion of different subtypes of stroke in China

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970094-2

7 January 2021

Incidence of cerebral hemorrhage in the Changsha community. A prospective study from 1986 to 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970094-2

7 January 2021

Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970094-2

7 January 2021

Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970094-2

7 January 2021

Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970094-2

7 January 2021

Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970094-2

7 January 2021

High-dose atorvastatin after stroke or transient ischemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970094-2

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970094-2

7 January 2021

Comparison of the protective effects of type III phosphodiesterase (PDE3) inhibitor (cilostazol) and acetylsalicylic acid on intestinal microcirculation after ischemia reperfusion injury in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970094-2

7 January 2021

Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970094-2

7 January 2021

The pharmacology of cilostazol

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970094-2

7 January 2021

Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970094-2

7 January 2021

Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970094-2

7 January 2021

Risk of hemorrhagic stroke with aspirin use: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970094-2

7 January 2021

Cerebral microbleeds are associated with lacunar stroke defined clinically and radiologically, independently of white matter lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970094-2

7 January 2021

Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970094-2

7 January 2021

Cilostazol alleviates cerebral small-vessel pathology and white-matter lesions in stroke-prone spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970094-2

7 January 2021

10.1016/S1474-4422(08)70094-2

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017